$PFE
Pfizer Inc. · NYSE · Healthcare
- Market cap
- 171.16B
- Volume
- 29.40M
- P/E
- 39.51
- Day range
- 29.81 – 30.32
- 52w range
- 23.62 – 30.44
- Analyst target
- 29.26
AI Summary
Generating a unique summary for PFE…
AI-generated for information only — not investment advice.
Share this ticker
$PFE -1.28% at 30.03 Bill Ackman and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/PFE
Company summary
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Institutional ownership
Institutions hold 69.05% · insiders 0.10% · 3,657 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 529.67M | $15.91B | 9.29% | 2026-06-30 |
| Vanguard Capital Management LLC | 372.15M | $11.18B | 6.53% | 2026-06-30 |
| State Street Corporation | 307.09M | $9.22B | 5.39% | 2026-06-30 |
| Geode Capital Management, LLC | 135.28M | $4.06B | 2.37% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 119.24M | $3.58B | 2.09% | 2026-06-30 |
| Fisher Asset Management, LLC | 109.07M | $3.28B | 1.91% | 2026-06-30 |
| Morgan Stanley | 96.35M | $2.89B | 1.69% | 2026-06-30 |
| NORGES BANK | 61.51M | $1.85B | 1.08% | 2026-06-30 |
| Northern Trust Corporation | 59.08M | $1.77B | 1.04% | 2026-06-30 |
| Bank Of New York Mellon Corporation | 57.88M | $1.74B | 1.02% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| BOURLA ALBERT | Chief Executive Officer | Purchase at price 26.34 per share. | 38.0K | 2026-08-12 |
| DAMICO JENNIFER B. | Officer | Sale at price 25.40 per share. | 3.3K | 2026-08-05 |
| BLAYLOCK RONALD E | Director | Purchase at price 25.46 per share. | 39.2K | 2026-08-05 |
| BUCKLEY MORTIMER J. | Director | Purchase at price 25.52 per share. | 37.6K | 2026-08-05 |
| DAMICO JENNIFER B. | Officer | Sale at price 25.70 per share. | 2.0K | 2026-06-09 |
| DAMICO JENNIFER B. | Officer | Stock Award(Grant) at price 0.00 per share. | 21.7K | 2026-03-03 |
| FONSECA LIDIA PH.D. | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 56.9K | 2026-02-25 |
| LANKLER DOUGLAS M | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 122.9K | 2026-02-25 |
| MCDERMOTT MICHAEL | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 37.9K | 2026-02-25 |
| BOURLA ALBERT | Chief Executive Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 491.6K | 2026-02-25 |
| DAMICO JENNIFER B. | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 17.6K | 2026-02-25 |
| SAHNI PAYAL | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 56.9K | 2026-02-25 |
Analyst ratings
Consensus score 2.50 (1 = strong buy, 5 = sell) · mean target 29.26
- JP MorganNeutralmain2026-10-09
- Cantor FitzgeraldNeutralmain2026-10-08
- ScotiabankSector Outperformmain2026-10-06
- HSBCHoldmain2026-09-10
- GuggenheimBuymain2026-08-07
- BMO CapitalOutperformmain2026-07-13
- GuggenheimBuymain2026-07-13
- B of A SecuritiesNeutralmain2026-07-10
- JP MorganNeutralmain2026-07-08
- Cantor FitzgeraldNeutralreit2026-07-06
Earnings
Next report: 2026-11-03
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 0.87 | 0.63 | 0.24 |
| 4Q2025 | 0.66 | 0.57 | 0.09 |
| 1Q2026 | 0.75 | 0.72 | 0.03 |
| 2Q2026 | 0.77 | 0.68 | 0.09 |
SEC filings
- N-PXAnnual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX2026-08-31Open
- 8-KCorporate Changes & Voting Matters2026-08-04Open
- 8-KCorporate Changes & Voting Matters2026-06-18Open
- 11-KAnnual report of employee stock purchase2026-06-16Open
- S-8Offering Registrations2026-05-05Open
- 8-KCorporate Changes & Voting Matters2026-04-27Open
- ARSAnnual Report to Shareholders2026-03-12Open
- 10-KPeriodic Financial Reports2026-02-26Open
- 8-KCorporate Changes & Voting Matters2026-02-03Open
- 8-KCorporate Changes & Voting Matters2025-12-16Open
Latest PFE news
- Pfizer And 2 Other AI Healthcare Stocks To Watch
Warning signs around heavily indebted AI infrastructure firms have grown louder after analysts raised the risk of a tech debt spiral, with some newer players struggling to finance data centers and high-end chips. That strain shifts attention toward more grounded uses of AI that address urgent problems such as healthcare. Investors seeking substance over hype may find this article useful. It profiles three AI powered healthcare stocks from our screener. The three stocks covered below are a...
Sat, 24 Oct 2026 22:09:44 +0000
- Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
NEW YORK, October 24, 2026--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today
Sat, 24 Oct 2026 15:18:00 +0000
- Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem
Pfizer has a plan to bounce back from recent obstacles.
Sat, 24 Oct 2026 07:20:00 +0000
- Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?
Pfizer (PFE) is back in focus after signing a research collaboration and license agreement with Enodia Therapeutics that gives the drugmaker access to Enodia’s Sec61 inhibitor programs for potential oncology and specialty treatments. Pfizer’s agreement with Enodia lands at a time when momentum in the shares has been rebuilding, with a 30 day share price return of 6.56% and a 90 day gain of 22.37%. The 1 year total shareholder return of 29.79% contrasts with a weaker 5 year total shareholder...
Sat, 24 Oct 2026 00:14:53 +0000
- Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.
Fri, 23 Oct 2026 13:17:53 +0000
- Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
One of these pharma stocks offers more income, but the other offers a safer dividend.
Fri, 23 Oct 2026 10:03:00 +0000
- What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
They definitely matter... up to a point.
Fri, 23 Oct 2026 00:20:00 +0000
- Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.
Thu, 22 Oct 2026 21:45:02 +0000